Phase II Iressa Versus Vinorelbine (INVITE)
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.
Non-Small-Cell Lung Carcinoma
DRUG: Gefitinib|DRUG: Vinorelbine
To compare ZD1839 and vinorelbine in terms of progression free survival
To compare ZD1839 and vinorelbine in terms of pulmonary symptom improvement weekly for 18 weeks.|To compare ZD1839 and vinorelbine in terms of quality of life 3 weekly for 18 weeks then 6 weekly.|To compare ZD1839 and vinorelbine in terms of adverse event profile continuous monitoring.|To compare ZD1839 and vinorelbine in terms of overall objective tumour response rate (complete response and partial response) 6 weekly to progression.|To compare ZD1839 and vinorelbine in terms of overall survival (time to death) continuous monitoring
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.